Corticosteroid in non-COVID-19 induced community-acquired pneumonia, a meta-analysis

Community-acquired pneumonia (CAP) is a significant global health burden with high incidence and mortality worldwide.1-4 Systemic corticosteroids possess broad-spectrum anti-inflammatory effects, and the controversy over their adjunctive treatment in CAP has persisted for decades.1 The benefits of corticosteroid use have been confirmed in patients with severe CAP (sCAP) caused by COVID-19.5,6 However, the role of corticosteroids in non-COVID-19 induced CAP remains uncertain.1,4,7-9
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research